Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Radj Gervais, Jose L. Perez-Gracia, Ji Youn Han, Margarita Majem, Martin D. Forster, Isabelle Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu Chou Su, Ayman Samkari, Erin H. Jensen, Julie Kobie, Bilal Piperdi, Paul Baas

Research output: Contribution to journal › Article › peer-review

143 Scopus citations

Fingerprint

Dive into the research topics of 'Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC'. Together they form a unique fingerprint.

Medicine & Life Sciences